Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Operation Supplement Safety (OPSS) Bethesda MD Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks Canada.ca FDA moves toward easing restrictions on certain peptides BioPharma Dive In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for